Objectives The increased frequency of very late (Ͼ1 year) stent thrombosis (VLST) has raised concerns with regard to the safety of sirolimus-eluting stents and paclitaxel-eluting stents (PES).
Early drug-eluting stents (DES) are burdened with late safety concerns-despite significant reductions in restenosisespecially very late stent thrombosis (VLST) (after 1 year), which was not previously observed with bare-metal stents (BMS) (1) (2) (3) (4) (5) . Increased VLST imposes important clinical dilemmas: 1) events occur out-of-hospital and uniformly result in acute myocardial infarction (MI), repeat revascularization, or death (4-7); 2) the duration of dual antiplatelet therapy (DAPT) in all patients is extended to 1 year or longer, and the optimal timing for discontinuation is unknown (4, 8) ; and 3) premature or unanticipated interruption of DAPT might impose additional risks for stent thrombosis (ST) (8) .
The zotarolimus-eluting stent (ZES) (Endeavor, Medtronic CardioVascular, Santa Rosa, California) was designed to retain the clinical anti-restenosis efficacy observed with previous DES designs (9, 10) . Pre-clinical studies have demonstrated improved early endothelialization compared with either sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) (TAXUS Express, Boston Scientific Corporation, Natick, Massachusetts) (11, 12) . Patient studies examining surrogate safety end points with intravascular ultrasound, optical coherence tomography, or vasomotor reactivity assessments have similarly demonstrated improved outcomes, unlike other early DES and more closely resembling BMS (13) (14) (15) (16) . In the prospective, randomized, single-blinded ENDEAVOR IV (Randomized Comparison of Zotarolimus-and PaclitaxelEluting Stents in Patients With Coronary Artery Disease) trial, ZES was found to be noninferior to PES with regard to the primary end point of 9-month target vessel failure (TVF) (17) . The purpose of this report is to highlight important differences in late clinical outcomes between ZES and PES after 3 years of follow-up.
Methods
Study population and procedures. The ENDEAVOR IV study design, patient eligibility, clinical end points, and principle outcomes at 1 and 2 years have been previously described (17, 18) . In brief, 1,548 patients Ն18 of age with a single de novo native coronary lesion with a diameter stenosis at least 50% but Ͻ100% by visual estimate, reference vessel diameter Ն2.5 mm and Յ3.5 mm, and lesion length Յ27 mm were enrolled. Patients were treated with 325 mg of aspirin within 24 h before the procedure, which was continued indefinitely. All patients received a loading dose of clopidogrel of at least 300 mg before the procedure, followed by 75 mg daily for at least 6 months. Continuation of clopidogrel beyond 6 months was at the discretion of the operator. Clinical follow-up was scheduled at 30 days and 6, 9, and 12 months and then yearly through 5 years. Protocolspecified angiographic follow-up was scheduled at 8 months after procedure in a subset of 328 patients (17) . The study was approved by the Institutional Review Board at each center, and all patients signed informed consent before the index procedure.
Patients were randomly assigned in 1:1 ratio to receive either ZES or PES. Patients, physicians performing follow-up assessments, data analysis personnel, statisticians, angiographic and intravascular ultrasound core laboratories, data safety monitoring board, and an independent clinical events committee were masked to stent assignments. After all patients underwent 1-year follow-up, randomization codes were provided to all sites, and upon Institutional Review Board approval, the stent information was disclosed to patients enrolled in the study.
The primary clinical end point was TVF (the composite of cardiac death, MI, or clinically driven target vessel revascularization) at 9 months after procedure. Diagnosis of Q-wave MI required new pathologic Q waves in Ն2 contiguous electrocardiographic leads and either symptoms consistent with acute myocardial ischemia or elevation of cardiac biomarkers. Non-Q-wave MI required elevated creatine kinase Ͼ2ϫ the upper laboratory limit with elevated creatine kinase-myocardial band in the absence of pathological Q waves. Secondary clinical end points included major adverse cardiac events (death, MI, emergency coronary artery bypass grafting, or clinically driven target lesion revascularization [TLR]). All events, including ST (the Academic Research Consortium [ARC] definition) (19) , were adjudicated by the Clinical Events Committee that remained blinded to the type of stent at each time point during the follow-up. Statistical analysis. The ENDEAVOR IV trial was designed to determine whether the primary end point (TVF at 9 months) of ZES was noninferior to PES. The sample size estimation was based on a noninferiority test with the Farrington-Manning approach (noninferior margin: 3.8%, alpha ϭ 0.05 [1-sided] significance level, with 84% statistical power to reject the null hypothesis of inferiority). Annual follow-up with reporting of key safety and effectiveness end points was pre-specified without adjustment for multiplicity.
Analysis was performed on an intention-to-treat basis. Baseline categorical variables were compared by chi-square or Fisher exact tests, and baseline continuous variables were compared by Student t tests. Hazard ratios (HRs) and their Up to 3 years, TLR was similar in ZES and PES patients (Table 2) , and the small TLR differences favoring PES at 1 year (delta 1.2%) (17) were reduced at 3 years (delta 0.4%) (Fig. 2D) . The percent of patients receiving DAPT at 3 years for ZES and PES treatment cohorts was 48.2% versus 52.1% (p ϭ 0.174). Definite or probable ST up to 3 years occurred in 8 ZES patients and 12 PES patients (1.1% vs. 1.7%, HR: 0.67, 95% CI: 0.28 to 1.64, p ϭ 0.380) ( Table 3) . Between 1 and 3 years, definite or probable VLST occurred in 1 ZES patient and 11 PES patients (0.1% vs. 1.6%, HR: 0.09, 95% CI: 0.01 to 0.71, p ϭ 0.004) ( Table 3 , Fig. 3 ). Among the 11 PES patients with VLST events, 6 were no longer receiving DAPT (4 with aspirin alone, and 2 without aspirin and clopidogrel), and 9 patients had an acute MI (Fig. 4) . The sole ZES patient with a VLST event was not receiving DAPT (without aspirin and clopidogrel) and had an acute MI (Fig. 4) .
Discussion
In the ENDEAVOR IV randomized trial, comparing ZES with PES, although the overall rate of ARC definite and The ENDEAVOR IV 3-Year Results probable ST did not differ during the initial 3 years of follow-up, there was a significant 1.4% absolute reduction in the rate of ARC definite or probable VLST with ZES compared with PES between 1 and 3 years (corresponding to a 91% relative risk reduction). Between 2 and 3 years, the rate of VLST remained unchanged with ZES (0.1% at both time points), whereas it doubled with PES (0.8% and 1.6%) (18) . Moreover, the trend toward lower rates of cardiac death or MI observed with ZES vs. PES at 2 years (3.4% vs. 5.1%, p ϭ 0.096) became significant at 3 years (3.6% vs. 7.1%, p ϭ 0.004), corresponding to 3.5% absolute reduction or to a 49% relative risk reduction. The striking reduction in VLST with ZES (from 11 events to 1 event) was observed with continued DAPT in approximately one-half the patients in both groups at 3 years. The ENDEAVOR IV trial is consistent with other studies that indicate that continued DAPT does not fully protect against VLST (20); 5 of the 12 patients with VLST were still receiving DAPT at the time of the event. The very low frequencyof ARC definite or probable VLST in ZES patients from the ENDEAVOR IV trial (0.1% up to 3 years) is similar to previous studies with BMS (6) 
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Figure 2. Time-to-Event Curves Up to 3 Years for Patients Treated With ZES Versus PES (A) Target vessel failure (TVF) (cardiac death, myocardial infarction [MI], or ischemia-driven target vessel revascularization). (B) MI. Continued on the next page. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 0 , 2 0 1 0 O C T O B E R 2 0 1 0 : 1 0 4 3 -5 0
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model, the magnitude of reduction in ST, comparing ZES with PES during 3-year follow-up in the ENDEAVOR IV trial, exceeded the threshold difference (0.14% change/year in absolute late ST) sufficiently to negate the clinical benefit of restenosis reduction when comparing DES with BMS (21). Whether these results are generalizable to patients undergoing PCI with other DES is still not clear. In the recent 18-month report from the SORT-OUT III (Danish Organisation for Randomised Trials with Clinical Outcome) randomized trial, incidence of ST increased from 0.2% at 9 months to 0.5% at 18 months in patients treated with SES, whereas there were no additional cases of ST for ZES (22) . More data are needed from studies of large unrestricted populations, such as the PROTECT (Patient Related OuTcomes with Endeavor versus Cypher stenting Trial), specifically designed to compare the frequency of late ST in 8,800 "real world" patients treated with either ZES or SES (23) . The explanation for reduced overall cardiac death and MI in the ENDEAVOR IV trial-predominantly, fewer MIs (early and late)-seems multifactorial. In ZES patients there was a significant decrease in periprocedural MIs (0.8% vs. 2.3%, p ϭ 0.014) that was related to improved periprocedural sidebranch patency (24) and a further decrease in MIs after 1 year (0.7% vs. 2.3%, p ϭ 0.017) that paralleled the reduction in VLST events. Importantly, these were not "insignificant" non-Q-wave MIs in the PES patients, because 47% of the peri-procedural MIs and 63% of the late (after 1 year) MIs were associated with creatine kinasemyocardial band elevations Ͼ10ϫ the upper normal limit. 
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Study limitations. This 3-year follow-up analysis from the ENDEAVOR IV trial is limited by study design factors. The sample size required to definitively examine differences in low event rate safety end points is several-fold greater than the 1,548 patients in this trial. Sample size considerations might also help to explain a reverse difference trend in ST up to 1 year, with higher-than-expected ST in ZES patients (0.9%) and lower-than-expected ST in PES patients (0.1%). The patients included in the ENDEAVOR IV trial had simple-to medium-complexity coronary lesions, and the results pertaining to safety cannot be extended to all patients with coronary disease. Knowledge of stent type by patients and physicians at the completion of 1-year follow-up might have influenced decision-making with regard to revascularization and duration of antiplatelet therapy.
Conclusions
Notwithstanding the limitations, the ENDEAVOR IV trial is the first randomized trial comparing different DES that demonstrates a significant improvement in both VLST and Data are presented as mean (SD) or n (%). *Canadian Cardiovascular Society (CCS) angina class.
CABG ϭ coronary artery bypass surgery; MI ϭ recent myocardial infarction (Ͼ72 h); PCI ϭ percutaneous coronary intervention; PES ϭ paclitaxel eluting-stent(s); ZES ϭ zotarolimus-eluting stent(s). Number of patients with events, (%) is the cumulative incidence rate. *Hazard ratio (HR) and 95%
confidence interval (CI) are calculated by Cox regression model.
Abbreviations as in Table 1 . Data expressed as n (%); n ϭ number of events at 3 years, (%) is the cumulative incidence rate.
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